Monitored long-term treatment with ibopamine in patients suffering from severe congestive heart failure.
50 patients with congestive heart failure underwent monitored long-term treatment aimed at evaluating the effect of ibopamine (SB-7505), the 3,4-diisobutyryl ester of N-methyldopamine, on their condition. Ibopamine was administered alone or in combination with traditional therapy mainly at a dose of 100 mg t.i.d. Clinical scores and NYHA (New York Heart Association) functional classes improved. Biochemical parameters showed no adverse modifications. Mild transient side-effects probably related to ibopamine occurred in two patients.
Z
Z
Avanzini
G C
GC
Bellogini
B
B
Brusoni
N
N
Ciampani
L
L
Dei Cas
U
U
Gazzola
G C
GC
Maggi
M
M
Mangiavacchi
M
M
Metra
L
L
Pinca
D000328:Adult; D000368:Aged; D001835:Body Weight / Q000187:drug effects; D002316:Cardiotonic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002908:Chronic Disease; D003846:Deoxyepinephrine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004298:Dopamine / Q000031:analogs & derivatives*; D005260:Female; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic; D013997:Time Factors
D002316:Cardiotonic Agents; C023487:ibopamine; D003846:Deoxyepinephrine; D004298:Dopamine